---
reference_id: "PMID:41158045"
title: "[A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib]."
authors:
- Wang Y
- Zhao W
- Yang C
- Zhang R
- Wang C
- Han C
- Li J
journal: Zhongguo Fei Ai Za Zhi
year: '2025'
doi: 10.3779/j.issn.1009-3419.2025.106.25
content_type: abstract_only
---

# [A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib].
**Authors:** Wang Y, Zhao W, Yang C, Zhang R, Wang C, Han C, Li J
**Journal:** Zhongguo Fei Ai Za Zhi (2025)
**DOI:** [10.3779/j.issn.1009-3419.2025.106.25](https://doi.org/10.3779/j.issn.1009-3419.2025.106.25)

## Content

1. Zhongguo Fei Ai Za Zhi. 2025 Aug 20;28(8):638-643. doi: 
10.3779/j.issn.1009-3419.2025.106.25.

[A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF 
p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib].

[Article in Chinese; Abstract available in Chinese from the publisher]

Wang Y(1), Zhao W(1), Yang C(1), Zhang R(1), Wang C(1), Han C(2), Li J(1).

Author information:
(1)Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 
250012, China.
(2)Department of Radiotherapy  Oncology, Affiliated Hospital of Shandong 
University of Traditional Chinese Medicine, Jinan 250011, China.

The v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene is one of the most 
critical proto-oncogenes and functions as a key regulator in the 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 
(ERK) signaling pathway. The incidence of BRAF mutations in non-small cell lung 
cancer (NSCLC) patients ranges from 1.5% to 5.5%, with BRAF V600 mutations 
accounting for approximately 30%-50% of all BRAF mutations, among which BRAF 
V600E represents the most prevalent mutation type. Currently, the combination of 
Dabrafenib and Trametinib has been recommended as first-line therapy for BRAF 
V600-mutant NSCLC by multiple domestic and international guidelines including 
National Comprehensive Cancer Network (NCCN), European Society of Medical 
Oncology (ESMO), and Chinese Society of Clinical Oncology (CSCO). However, there 
are no clear targeted treatment recommendations for BRAF non-V600 mutations. 
Although case reports suggest that Dabrafenib combined with Trametinib may be 
effective for patients with BRAF non-V600 mutations, the efficacy and safety 
require further validation due to limited sample size and lack of large-scale 
clinical trial data. This article reports a case of NSCLC with a rare BRAF 
insertion and deletion mutation that responded well to the treatment of 
Dabrafenib in combination with Trametinib, aiming to enhance clinicians' 
understanding of such NSCLC cases with extremely rare mutation and provide a 
reference for future treatment strategies. .

Publisher: 【中文题目：达拉非尼联合曲美替尼治疗BRAF p.L485_T488delinsF突变转移性非小细胞肺癌1例】 
【中文摘要：鼠类肉瘤病毒癌基因同源物B（v-Rafmurine sarcoma viral oncogene homolog B, 
BRAF）是最重要的原癌基因之一，是丝裂原活化蛋白激酶（mitogen-activated protein kinase, 
MAPK）/细胞外信号调节激酶（extracellular signal-regulated kinase, 
ERK）信号通路的关键调节因子。BRAF突变在非小细胞肺癌（non-small cell lung cancer, 
NSCLC）患者中的发生率为1.5%-5.5%，其中BRAF V600突变占所有BRAF突变的30%-50%，BRAF 
V600E是最常见的突变类型。目前，达拉非尼联合曲美替尼已被美国国立综合癌症网络（National Comprehensive Cancer Network, 
NCCN）、欧洲肿瘤内科学会（European Society of Medical Oncology, ESMO）、中国临床肿瘤学会（Chinese 
Society of Clinical Oncology, CSCO）等多个国内外指南推荐作为BRAF 
V600突变NSCLC的一线治疗选择。然而，针对BRAF非V600突变，目前尚无明确的靶向治疗推荐。尽管个案报道提示达拉非尼联合曲美替尼对部分BRAF非V600突变患者可能有效，但由于病例数量有限且缺乏大样本临床试验数据，其疗效和安全性仍需进一步验证。本文报道了1例经达拉非尼联合曲美替尼治疗有效的罕见BRAF插入缺失突变（BRAF 
p.L485_T488delinsF）的NSCLC病例，旨在提高临床医生对该类罕见突变病例的认识，并为未来治疗策略的探索提供参考。 】 
【中文关键词：肺肿瘤；BRAF突变；达拉非尼；曲美替尼；靶向治疗】.

DOI: 10.3779/j.issn.1009-3419.2025.106.25
PMCID: PMC12580391
PMID: 41158045 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: The authors declare that 
they have no competing interests.